Understand resistance before the clinic

Identify the primary drivers of clinical trial success with ENCER cancer models.

Environmental cellular reprogramming (ENCER) cancer models for your drug and indication

Treatment resistance is responsible for 90% of cancer deaths, however, existing pre-clinical models do not produce the data necessary to understand and prevent it.

Our ENCER models mimic treatment course, environment, and duration to create bespoke cancer models that represent outcomes across natural patient diversity.

Partner with us
Our Model

Model

We work with you to define ENCER parameters, including cancer type, tumor microenvironment, drug dosing parameters, and standard of care control.

Reprogram

Cancer models are reprogrammed in our proprietary ResCu device by modulating the tumor microenvironment and drug exposure, ensuring that heterogeneity is preserved and sub-cellular populations develop resistance mechanisms found in patient subpopulations.

Map

Using longitudinal multi-omic data from single cell sequencing, we identify mechanisms that drive resistance and map their interactions to create complex resistance networks.

Applications

Target Selection
Mode of Action
Drug Screening
Candidate Selection and optimization
Combination Treatment
Development
Patient Population Selection
Indication Expansion
Personalized Diagnostics and Treatment
In-Licensing Analysis
Patient Population Selection
Indication Expansion
Personalized Diagnostics and Treatment
In-Licensing Analysis
Dose Selection
Portfolio Analysis
Target Selection
Mode of Action
Drug Screening
Mode of Action
Drug Screening
Candidate Selection and optimization
Combination Treatment
Development
Patient Population Selection
Indication Expansion
Personalized Diagnostics and Treatment
In-Licensing Analysis

Capture up to 92% of clinically-identified resistance mechanisms in vitro

ENCER cancer models generate human-relevant changes in the genome, transcriptome, epigenome, proteome, lipidome, and metabolome that other methods can’t.

CRISPR

CRISPR excels at artificially engineering biology and it fails to accurately simulate nuanced natural processes like resistance pathways.

Organoids

Sustained artificial stimulation of signaling pathways to develop 3D structures eliminates the nuance of naturally-evolving resistance.

Animal models

Mouse signaling factors trigger different responses than human signal factoring, skewing natural cell response and biology.

ENCER models

Our models mimic treatment course and duration within a human-relevant environment, enabling resistance to evolve like it would within a patient.

Hand with test tube
A group of people working
two men smiling

Become a resistance fighter

At resistanceBio, our goal is to stop treatment resistance before it happens. Come join us to create state-of-the-art models and push the next generation of cancer therapies forward.

See our open positions

Get answers with ENCER

Join top five biopharmas closing the gap between their pre-clinical and clinical data

Thank you for your message!
Our team will get back to you shortly.
Oops! Something went wrong while submitting the form.